The Food and Drug Administration (FDA) has approved Caplyta ® (lumateperone) as an adjunctive therapy with antidepressants for the treatment of major depressive disorder (MDD) in adults.
Three medical experts review the evidence around how antidepressants may affect the gut microbiome, and what this could mean ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback